0.30Open0.45Pre Close151 Volume41 Open Interest35.00Strike Price4.31KTurnover97.11%IV3.96%PremiumMay 9, 2025Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.20Extrinsic Value100Contract SizeAmericanOptions Type0.2339Delta0.2050Gamma169.30Leverage Ratio-0.3079Theta0.0002Rho39.60Eff Leverage0.0047Vega
TG Therapeutics Stock Discussion
TG Therapeutics Crushes Earnings: MS Drug BRIUMVI Drives 137% Growth, Company Turns Profitable
Game-Changing MS Treatment? BRIUMVI Single-Dose Trial Reveals Breakthrough Potential
Game-Changing MS Treatment: BRIUMVI Reveals Exceptional Real-World Safety Profile
Medical Journals Reveal Breakthrough: BRIUMVI Succeeds Where Other MS Treatments Fall Short
How TG Therapeutics Transformed from Clinical-Stage to Profitable Biotech with 250% Revenue Growth
Can BRIUMVI Succeed Where Other MS Treatments Failed? New Clinical Data Reveals Promising Results
Larger Image: tradingview.com...
$TG Therapeutics (TGTX.US)$
No comment yet